With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Endocyte, imaging, prostate cancer-specific, Purdue | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
